SIRPA and neoplasm: An interesting report had highlighted that the role of Glutaminyl cyclase isoenzyme (QPCTL) is critical for pyroglutamate formation on CD47 at the SIRPα binding site (87) and inhibition of QPCTL activity enhances antibody-dependent cellular phagocytosis and cellular cytotoxicity of tumor cells.